

ASX RELEASE

Volpara provides additional supplementary information on major contract win with leading US outpatient diagnostic imaging provider

Wellington, NZ, 8 October 2021: <u>Volpara Health Technologies Limited</u> ("Volpara," "the Group," or "the Company"; ASX:VHT), a global health technology software leader providing an integrated platform for the delivery of personalised breast care, provides the following supplementary information regarding the major contract announced on Tuesday 5 October 2021.

The contract, with Akumin Corp., a subsidiary of Akumin, Inc., is effective immediately with installation expected to occur within the next 3 to 6 months. As previously announced the contract is for an initial period of 5 years with annual payments upfront, however the customer can terminate the contract after 3.5 years.

Authorisation & Additional Information

This announcement was authorised by the CEO of Volpara Health technologies Limited.

ENDS

For further information, please contact:

Ralph Highnam, CEO Hannah Howlett

Volpara Health Technologies WE Communications

<u>ralph.highnam@volparahealth.com</u> <u>WE-AUVolpara@we-worldwide.com</u>

t: +64 21 149 0541 t: +61 407 933 437

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a health technology software company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 39 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020, and has made two significant acquisitions in MRS Systems, Inc. (patient tracking software), and CRA Health, LLC (risk and genetics software). VHT is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com.